Jinyu Bio-technology Co., Ltd. (Jinyu), the largest animal vaccine company in China, announced that it will open a vaccine research lab and office at the new K-State Office Park Phase II building in the KC Animal Health Corridor. The company will focus its Corridor location on research and design of vaccines for swine and cattle, as well as continuing education materials for Chinese companies and veterinarians.
“Manhattan and Kansas State University are at the forefront of animal health research that is relevant to the Chinese animal agriculture industry and the world,” said Mr. Chongyu Zhang, chairman, Jinyu Bio-technology Co., Ltd. “Jinyu is the largest animal vaccine company in China and is fast growing internationally. We are looking forward to developing a long-term, mutually beneficial relationship with partners in the region.”
Jinyu USA will partner with Kansas State University, the City of Manhattan and the State of Kansas to develop new animal health products that can be marketed in China, Asia, Africa and the U.S. The company is also considering the addition of future manufacturing facilities in the Corridor.
“The addition of Jinyu Bio-technology to the KC Animal Health Corridor is truly a partnership of innovation and expertise,” said Kansas Commerce Secretary Antonio Soave. “We, as a state, must continue to engage excellent biotech companies like Jinyu, as Kansas continues to become one of the leading locations for bioscience in the nation.”
Jinyu plans a 2,400-sq. ft. lab facility, three offices and 800 square feet of clean room space at the K-State Office Park Phase II building, employing four to six scientific researchers. The KSU Foundation will break ground on the Phase II building in July 2017 and the company’s space will become available in 2018.
“When university-focused companies like Jinyu Bio-technology Co., Ltd., locate adjacent to K-State’s campus, partnerships develop with faculty expertise and research to promote real-world application and discovery,” said Greg Willems, KSU Foundation president and CEO. “The K-State Office Park advances opportunity for these current and future collaborations to boldly move K-State — and the needs of a global community — forward.”
“Kansas State University has many partnerships with the industry, though this partnership is the first one with a Chinese animal health company,” said Jishu Shi, professor and director, U.S. China Center for Animal Health at Kansas State University. “It will accelerate the commercialization of novel discovery and development generated by K-State scientists.”
KCADC was proud to work with a number of regional partners in attracting Jinyu to the region: State of Kansas; Kansas Department of Commerce; City of Manhattan, Kansas; Manhattan, Kansas Area Chamber of Commerce; Kansas State University; Kansas State University Institute for Commercialization; Kansas State University Research Foundation; Kansas State University College of Veterinary Medicine; Kansas State University US-China Center for Animal Health; and the KC Animal Health Corridor.
“The KC Animal Health Corridor’s international reputation is a strategic advantage for more and more animal health companies. We are thrilled to welcome Jinyu to our Corridor community and look forward to the company’s leadership in the effort,” said Kimberly Young, president of the KC Animal Health Corridor.
About the KC Animal Health Corridor
Companies with a business location in the KC Animal Health Corridor account for more than half of the sales generated by the global animal health industry. The Corridor, anchored by Manhattan, Kansas, and Columbia, Missouri, is home to more than 300 animal health companies, representing the largest concentration in the world. For more information, visit KCanimalhealth.com.
About Jinyu Bio-technology Co., Ltd.
Jinyu Bio-technology Co. was founded in 1993 and is the largest animal vaccine company in China. Jinyu has a complete portfolio for animal vaccines, which includes ruminants, swine and poultry. It is the leading manufacturer of FMD vaccines in China. Jinyu is also one of the few Chinese animal health companies whose products meet international standards. The firm was selected as the 2016 Best Company in Asia and Australasia by Animal Pharm. Jinyu exported vaccines to a number of countries such as Mongolia, Bangladesh and Egypt. Jinyu’s average annual sales growth rate has been over 30% since 2012. In the most recent financial year, Jinyu recorded 17% sales growth with a 38% net profit margin.
Jinyu has China's uniquely designated national animal vaccine engineering lab, BSL-3 lab and animal facilities, where it develops its pipeline of advanced animal vaccines. Jinyu is also currently constructing a new biological science and technology industrial park in Hohhot that is scheduled to open in 2018. The Jinyu International Biotechnology Industrial Park covers an area of 110 acres and has planned a US$363 million investment for phase one to build up an animal vaccine production and R&D base. By recognizing innovations as its core competitiveness and a strong engine for growth, Jinyu visions to lead the China animal health industry by expanding international markets in the next five years. Visit www.jinyu.com.cn/en/.
There are no comments
Please login to post comments